The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

UNICEF is working to strengthen under-resourced health systems around the world to improve outcomes for children and family ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly (NYSE: LLY) is taking a shot at developing one. With the appointment of a new chief ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Eoneren/E+ via Getty Images Short interest for healthcare stocks in S&P 500 increased during September end vs.

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...